Cadre Holdings (CDRE) receives a buy rating due to its strong market position and over 80% of its products tied to recurring replacement demand, ensuring steady sales. Despite Q1 margin weakness caused by acquisition-related factors, margins are expected to improve in the second half of 2026 as shipment volumes and product mix get better. Trading at 12.2 times forward EBITDA, CDRE could see further upside if it achieves margin expansion, backlog conversion, and deleveraging goals.
Halper Sadeh LLC is investigating whether the sales and mergers involving Utz Brands, BioLife Solutions, and Northrim BanCorp provide fair financial terms to their shareholders. The firm suspects insiders might gain benefits not available to ordinary...
Major cryptocurrencies like Bitcoin and Ether remained mostly unchanged amid modest trading volumes, while semiconductor stocks showed signs of stabilization after a sharp selloff. Samsung reported a 250-fold profit increase due to AI memory shortage...
Ethereum's 11th anniversary is sparking increased interest, with BlackRock clients buying over $20 million in ETH while Bitcoin ETF outflows total $60 million. A whale recently withdrew 40,000 ETH from Binance, signaling potential long-term holding. ...
ArcelorMittal posted robust second quarter 2026 results with EBITDA of $2.1 billion, reflecting structurally improved margins and a $155 per tonne margin, boosted by strategic investments and a new European trade quota system. Net income reached $0.7...
Mesoblast announced $36 million in net revenue for Q4 and $115 million for the first full year following FDA approval of its Ryoncil therapy, used to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The company is expa...
